Beatriz García Fernández-rekin lankidetzan egindako argitalpenak (11)

2021

  1. Alterations in the Expression of the Genes Responsible for the Synthesis of Heparan Sulfate in Brains With Alzheimer Disease

    Journal of neuropathology and experimental neurology, Vol. 80, Núm. 5, pp. 446-456

  2. The genes encoding small leucine-rich proteoglycans undergo differential expression alterations in colorectal cancer, depending on tumor location

    Cells, Vol. 10, Núm. 8

2020

  1. Heparan sulfate proteoglycans undergo differential expression alterations in alzheimer disease brains

    Journal of Neuropathology and Experimental Neurology, Vol. 79, Núm. 5, pp. 474-483

  2. Miki (Mitotic Kinetics Regulator) Immunoexpression in Normal Liver, Cirrhotic Areas and Hepatocellular Carcinomas: a Preliminary Study with Clinical Relevance

    Pathology and Oncology Research, Vol. 26, Núm. 1, pp. 167-173

2018

  1. Brains with sporadic Creutzfeldt-Jakob disease and copathology showed a prolonged end-stage of disease

    Journal of Clinical Pathology, Vol. 71, Núm. 5, pp. 446-450

  2. Establishing cut-off points with clinical relevance for bcl-2, cyclin D1, p16, p21, p27, p53, Sox11 and WT1 expression in glioblastoma - a short report

    Cellular Oncology, Vol. 41, Núm. 2, pp. 213-221

  3. Heparan sulfate proteoglycans undergo differential expression alterations in left sided colorectal cancer, depending on their metastatic character

    BMC Cancer, Vol. 18, Núm. 1

2017

  1. Heparan sulfate proteoglycans and heparanases in Alzheimer’s disease: Current outlook and potential therapeutic targets

    Neural Regeneration Research

  2. Upregulated Expression of Heparanase and Heparanase 2 in the Brains of Alzheimer's Disease

    Journal of Alzheimer's Disease, Vol. 58, Núm. 1, pp. 185-192

2016

  1. Heparanase and heparanase 2 display differently deregulation in neuroendocrine tumors, depending on their differentiation grade

    Histology and Histopathology, Vol. 31, Núm. 1, pp. 73-81

2014

  1. Neuroendocrine tumors show altered expression of chondroitin sulfate, glypican 1, glypican 5, and syndecan 2 depending on their differentiation grade

    Frontiers in Oncology, Vol. 4 FEB